Eli Lilly’s Copycat Insulin Gets Interchangeability Nod from FDA

Eli Lilly has received approval for the interchangeable use of its insulin biosimilar with Sanofi’s Lantus. Patients will now be able to ask for Lilly’s biosimilar at the pharmacy as a substitution for Landus, which runs $300 dollars for a 10 mL bottle out of pocket. The move comes as public furor and legislative action builds up against pharma for the cost of insulin, a lifesaving drug that was intended to be as cheap as possible when its patent was sold decades ago.

According to Fraiser Kansteiner, “Even as lawmakers work to counter high insulin costs, the current situation remains bleak for some patients. According to a recent study from the Annals of Internal Medicine, more than 1 million adults in the U.S. have to ration their insulin because of the current pricing landscape.”

To read more, click here.

(Source: Fierce Pharma, November 18^th, 2022)